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Abstract 
Background: Diagnosis of Plasmodium falciparum is often based on detection of histidine-rich protein 2 (HRP2) in 
blood. Most HRP2-based assays have high sensitivity and specificity; however, authors have suggested that antibod-
ies (Ab) to HRP2 could reduce assay sensitivity. This study sought to characterize the antibody response to HRP2 with 
respect to prevalence, class, subclass, affinity, and age distribution in Cameroonian children and adults residing in an 
area with high P. falciparum transmission.
Methods: Plasma samples from 181 Cameroonian children and adults who had been repeatedly exposed to P. 
falciparum and 112 samples from American adults who had never been exposed were tested for IgG Ab to HRP2. For 
comparison, Ab to the merozoite antigens MSP1, MSP2, MSP3 and the pregnancy-associated antigen VAR2CSA were 
measured using a multiplex bead-based assay. In addition, 81 plasma samples from slide-positive individuals were 
screened for IgM Ab to HRP2.
Results: As expected, children and adults had IgG Ab to MSP1, MSP2 and MSP3, antibody levels increased with age, 
and only women of child-bearing age had Ab to VAR2CSA; however, no convincing evidence was found that these 
individuals had an acquired antibody response to HRP2. That is, using two sources of recombinant HRP2, identical 
results were obtained when plasma from 110 Cameroonian adults and 112 US adults were screened for IgG Ab. Fur-
ther studies showed that antibody prevalence and levels did not increase with age in Cameroonians between ages 5 
and >80 years. Although a few samples from slide-positive Cameroonians had IgM values slightly above the American 
cut-off, it was unclear if the individuals had a true IgM response to HRP2 or if the values were due to non-specific 
binding from elevated immunoglobulin levels associated with infection. Data from prediction models showed a pau-
city of Class II T cell epitopes in HRP2.
Conclusions: These data support the conclusion that most individuals in malaria-endemic areas do not produce 
an acquired humoral response to HRP2. The absence of Ab helps explain why HRP2-based assays are able to detect 
nanogram amounts of HRP2 and why HRP2 continues to circulate for a long time after parasite clearance.
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Background
In 1990, histidine-rich protein 2 (HRP2) was identified 
as a potential target for diagnosis of Plasmodium fal-
ciparum infections [1]. Soon thereafter, the approach 
for diagnosing malaria by detecting HRP2 in blood was 
validated when a field trial in Thailand (1993) reported 
that an antigen-capture ELISA for HRP2 [2] had 98% 
sensitivity and 96.2% specificity [3]. Since then, numer-
ous rapid diagnostic immuno-chromatographic tests 
(RDT) for detecting HRP2 have been developed and used 
worldwide as an alternative to microscopy for diagnos-
ing malaria. The WHO initiative launched in 2012 for 
control of malaria, T3: Test, Treat, Track, relies heavily 
on the use of RDT for diagnosis of malaria [4]. In addi-
tion, recent studies have measured the amount of HRP2 
in blood as an index of whole-body parasite burden [5, 6] 
and to estimate disease pathology [7]. HRP2 has proven 
to be a valuable protein for diagnosis of malaria since it 
is produced by ring and trophozoite-stage parasites and 
secreted into plasma [6, 8]. Because infected erythro-
cytes containing trophozoite-stage parasites sequester in 
deep vascular tissues, detection of soluble HRP2 in blood 
plasma allows for diagnosis of malaria in individuals who 
are slide-negative by microscopy.
Since rabbits and mice readily produce antibodies (Ab) 
when immunized with recombinant HRP2, it is assumed 
HRP2 is immunogenic in people infected with P. falcipa-
rum. Accordingly, a number of authors have speculated 
that Ab to HRP2 might reduce the sensitivity of HRP2-
based assays [3, 9, 10], since Ab could complex with solu-
ble or parasite-associated HRP2 and block its detection 
in antigen-capture assays. Surprisingly, few groups have 
studied Ab to HRP2 [9–11]. In a drug-treatment study 
in India, Biswas et  al. reported that soluble HRP2 and 
IgM Ab to HRP2 were present in P. falciparum-infected 
patients at enrolment, that both HRP2 and IgM to HRP2 
declined following drug treatment, and that anti-HRP2 
IgG Ab were present on days 15 and 28 days after drug 
treatment [10]. However, in a brief report, Das et al. tested 
plasma by ELISA from individuals living in a malaria-
endemic region of India for Ab to HRP2 and found no 
difference in optical density (OD) values between 15 
naive and 45 exposed individuals [11]; however, the lack 
of a positive control for the assay complicated interpreta-
tion of the results. More recently, Ho et al. using a simi-
lar ELISA reported that 25% of plasma samples (n = 75) 
collected from patients with acute malaria in Cambodia, 
Nigeria and the Philippines had anti-HRP2 Ab [9], with 
the majority of samples having OD values only one to 
three times above the cut-off. These results suggest that 
HRP2 is either not highly immunogenic in humans or the 
Ab response is short-lived.
Because of the potential for anti-HRP2 Ab to reduce 
the sensitivity of HRP2-based diagnostic assays, this 
study sought to establish the prevalence, class, subclass, 
affinity, and age distribution of Ab to HRP-2 in Cameroo-
nian children and adults, aged 5 to 82  years of age, resid-
ing in a malaria-endemic region with high P. falciparum 
transmission. For comparison, Ab to the merozoite anti-
gens MSP1, MSP2, MSP3 and the pregnancy-associated 
antigen VAR2CSA were measured using a bead-based 
multiplex assay. The study design tested the hypothesis 
that if Ab to HRP2 were produced by an antigen-specific 
acquired humoral immune response, then Ab would be 
present in individuals who had been exposed but not in 
unexposed individuals, and that the Ab response would 
be boosted by re-exposure. Plasma samples from 181 
Cameroonian children and adults (45% of whom were 
slide-positive from malaria) were tested and compared 
with data from 112 Americans who had not been exposed 
to malaria. Overall, results for MSP1, MSP2, MSP3 and 
VAR2CSA were as expected; however, there was no solid 
evidence that individuals living in a malaria-endemic area 
had developed an acquired humoral immune response to 
HRP2.
Methods
Study design, plasma samples and clinical information
The first study compared Ab levels to HRP2, MSP1, 
MSP2, MSP3, and VAR2CSA between 110 Cameroo-
nian and 112 American adults. Cameroon plasma sam-
ples were collected as part of a cross-sectional study 
between 1994 and 1999 and included subjects 18 and 
80  years of age residing in Simbok, where residents 
received an estimated 566 infectious bites per year at 
the time of collection [12]. The USA plasma samples 
were acquired over the last 20  years from individu-
als residing in the USA, including plasma purchased 
from commercial blood suppliers (e.g., Interstate Blood 
Bank), blood donors for in  vitro cultures of P. falcipa-
rum, discarded coded sample from clinical laborato-
ries, and adults, including pregnant women, residing in 
Hawaii. In the study evaluating acquisition of Ab with 
age, children between the ages of 5 and <18 years were 
included, providing a panel of 132 individuals. The panel 
included: 5 to 10 years old (n = 9), 10–5 years (n = 12); 
16–20 years (n = 8); 21–25 (n = 15) years; 26–30 years 
(n =  19); 31–40  years (n =  29); 41–50  years (n =  13); 
and >50 years (n = 27). To determine if active P. falcipa-
rum infection induced IgM Ab, plasma from 81 individ-
uals (49 children and 32 adults) who were slide-positive 
for malaria were tested. Overall, plasma from 181 Cam-
eroonian and 112 US individuals were screened for Ab 
to HRP2.
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Antigens
Two recombinant HRP2 proteins were used: recom-
binant HRP2-(A) was kindly provided by B. Pasloske 
(M-HRP2 4.22.92; Affymax Research Institute, Palo Alto, 
CA, USA) and recombinant HRP2 (B) was provided by 
D. Sullivan (Johns Hopkins University) [13]. For com-
parison, four additional malarial antigens were used, 
including a recombinant protein from the C-terminal 
regions of the merozoite surface protein 1 (MSP1-42) 
and MSP-2 produced in Escherichia coli provided by C. 
Long (Malaria Vaccine Development Branch, NIAID, 
NIH, USA); the C-terminal region of MSP3 expressed in 
E. coli (m.w. 22,000) from the Pasteur Institute; and, full-
length recombinant VAR2CSA (FV2) produced in bacu-
lovirus provided by A. Salanti, University of Copenhagen. 
VAR2CSA was used, even though Ab to it are pregnancy-
associated, because Americans have higher background 
levels to this protein than to other recombinant malarial 
antigens.
The multiplex analyte platform for antibodies
Malarial antigens were coupled to SeroMap micro-
spheres as previously described [14]. To determine the 
optimal amount of HRP2 to use, 1, 2, 4, 8, and 16 µg of 
recombinant HRP2-(A) and HRP2-(B) were coupled to 
106 SeroMap microspheres. Essentially identical results 
were obtained with both recombinant proteins when 
coupled at equivalent concentrations. In the current 
study, beads were coupled with 4 µg of HRP2-(A) (opti-
mal) but only 1 µg of HRP2-(B) per 106 microspheres as 
the available supply was limiting. The lower values for 
HRP-(B), (e.g., Fig. 1) are due to the lower amount of pro-
tein coupled, not to protein quality. The malarial antigens 
MSP1-42, MSP-2 and MSP-3 were coupled at 1  μg/106 
microspheres and full-length VAR2CSA at 3  µg/106 
microspheres. In optimizing the assay, all antigen-cou-
pled microspheres were tested against pools of positive 
and negative control plasma in the monoplex and multi-
plex format. No difference in results was obtained when 
the antigens were used alone or combined. In the assay, 
50  μl of plasma at a 1:100 dilution in PBS  +  1% BSA 
(unless otherwise specified) was incubated with 50 μl of 
the microsphere mix (pool of 2000 microspheres coupled 
to each antigen) at RT for 60 min on a shaker at 600 rpm. 
Microspheres were washed twice with 200  μl of PBS-
0.05% Tween and then once with 200 μl of PBS + 1% BSA 
per well. The microspheres were resuspended and incu-
bated with 100 μl of either: (1) anti-human IgG coupled 
to Phycoerythrin diluted in PBS  +  1% BSA at 2  µg/ml 
(R-Phycoerythrin AffiniPure F(ab’) Fragment Goat Anti-
Human IgG, Fcγ Fragment Specific, Jackson ImmunoRe-
search Lab, Inc., Cat# 109-116-170); or, (2) or anti-human 
IgM-phycoerythrin (R-Phycoerythrin AffiniPure F(ab’) 
Fragment Donkey Anti-Human IgM, Fc5μ Fragment Spe-
cific, Jackson ImmunoResearch Lab, Inc., Cat# 709-116-
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Fig. 1 Titration of monoclonal antibodies to recombinant HRP2. Tenfold serial dilutions of murine ascites fluid containing monoclonal Ab to HRP2 
(2G12, 87 and 1E1) and an irrelevant mAb (A2C7—negative control) were assayed on HRP2-coupled microspheres. Results are the mean ± SD for 
triplicate samples (technical replicates). The amount of HRP2-B coupled to the microspheres was fourfold lower than HRP2-A, explaining the differ-
ence in MFI values between the two datasets. The MFI observed with 1E1 (IgM) might be low, because the secondary reagent only detected IgM by 
light-chain reactivity
Page 4 of 14Taylor et al. Malar J  (2017) 16:58 
(RT) for 60 min on a shaker, microspheres were washed 
and resuspended in 100 μl of PBS + 1% BSA per well and 
read in a Liquichip L100 reader (Qiagen, Valencia, CA, 
USA) programmed to read at least 100 beads per antigen. 
Results are expressed as median fluorescent intensity 
(MFI). All experiments were repeated at least twice using 
two different sets of antigen-coated beads.
Monoclonal antibodies (mAb) to HRP
Three mAb to HRP2 (mAb 87, mAb 2G12-1C12, and mAb 
1E1-A9) and an irrelevant mAb (A2C7-A3B11) were used. 
Previous studies showed that mouse mAb87 (IgM) detects 
HRP2 by metabolic immunoprecipitation and western 
blotting [15]; 2G12 (IgG) binds to the sequence DAH-
HAADAHH in the repeat region of HRP2 and 1E1 (IgM) 
binds to AHHAHHV [16, 17]. MAb 2G12 and 1E1 work 
especially well together in an HRP2-based diagnostic 
ELISA [2]. Sequencing studies showed that epitopes recog-
nized by 2G12 and 1E1 are present in 100% (448/488) and 
99.3% (445/448) of P. falciparum isolates, respectively [17]. 
The mAb were used in this study to verify that these two 
major epitopes of HRP2 that are present in multiple strains 
were correctly displayed on the coupled microspheres. 
Serial dilutions of the anti-HRP-2 and control mAb were 
incubated with the HRP-2 coupled microspheres as 
described above. Following incubation, the microspheres 
were incubated with 100  μl of R Phycoerythrin-coupled 
AffiniPure F(ab’) Fragment Donkey Anti-Mouse IgG 
(H  +  L) (Jackson ImmunoResearch Lab, Inc., Cat# 715-
116-150) diluted in PBS + 1% BSA at 2 µg/ml.
Per cent of high avidity antibody to HRP2
The avidity assay was performed as previously described 
with minor modifications [18]. Briefly, plasma was 
diluted 1:300 in 1% BSA-PBS and 50  µl was added to 
duplicate wells containing 50  µl of antigen-coupled 
microspheres (2000 microspheres/test) and incubated for 
1 h on a shaker. After incubation, 100 µl of 3 M NH4SCN 
in 1% BSA-PBS was added to half the wells and 100 µl of 
1% BSA-PBS was added to the other half. After 30-min 
incubation, the wells were washed and incubated with 
R-phycoerythrin-labelled anti-human IgG, washed, and 
analysed by Liquichip L100 as described above. Avidity 
was calculated by (MFI obtained from wells incubated 
with salt)/(MFI obtained from corresponding control 
wells) × 100 for each antigen. Positive and negative con-
trols were included on each plate.
Indirect immunofluorescent assay (IFA)
Plasmodium falciparum (FVO) were cultured in  vitro 
until parasitaemia reached ~5 to 10% and blood smears 
were prepared. Following fixation in cold acetone, 
selected plasma samples were diluted 1:50 and  ~15  μl 
was applied to the smears for 30 min at RT. Slides were 
washed with PBS and incubated with 15  μl of a 1:100 
dilution of fluorescein isothiocynate (FITC)-labelled 
anti-human IgG (AffiniPure F(ab’) Fragment Goat Anti-
Human IgG, Fcγ Fragment Specific, Jackson Immu-
noResearch Lab, Inc., Cat# 109-096-098) or anti-human 
IgM (rabbit anti-human IgM (Fc specific, Sigma, Cat 
# 14121 followed by FITC-AffiniPure F(ab’) Fragment 
Goat Anti-Rabbit IgG (H  +  L), Jackson ImmunoRe-
search Lab, Inc., Cat# 111-096-003). MAb 2G12 and IE1 
and normal mouse plasma were used as a positive and 
negative controls, respectively, because the MAb give a 
distinct pattern of fluorescence when bound to HRP2. 
After 30 min, smears were washed, mounted in mount-
ing medium (Barbital buffer, pH 8.5 in 50% glycerol), 
and examined using a Zeiss Axiovision HBO 100 fluo-
rescent microscope.
Algorithms for detecting potential Class II T cell epitopes
Based on information in the original sequencing 
study [19], P. falciparum NF135/5.C10 GenBank: 
ETW43476.1 was used in the analysis and included the 
28 amino acids prior to the repeat sequence, the repeat 
sequence (RII), and 9 amino acid C-terminal region. 
The sequence was analysed for MHCII binding predic-
tions using the IEDB analysis resource Consensus tool 
based on data for 4/17/2-13 [20, 21]. The predicted 
outputs are given as IC 50 nM binding for the combi-
natorial library and SMM_align; with scores  <50  nM 
considered to be high,  <500  nM intermediate affinity, 
and <5000 nM as low affinity binding. Allelic/frequency 
distributions for Africa were obtained from the Allelic 
Frequency Net Database in Worldwide Populations 
[22].
Statistical analysis
Comparisons of MFI between different groups are pre-
sented as mean  ±  SD. Cut-off for sero-positivity was 
based either on mean ±3 SD or area under the receiver 
operator curves (ROC), as specified in the text.
Ethical approval
Coded, archival plasma samples and clinical information 
were used in this study. It received exemption from the 
Committee on Human Subjects, University of Hawaii 
(CHS #23048). The Cameroonian samples and data were 
originally collected with approval of the University of 
Yaoundé 1 Ethics Committee, Georgetown University 
(IRB #1994-158), and Office of Human Research Protec-
tion, Department of Health and Human Services(single 
project assurance #S-9601-01).
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Results
Assessing if recombinant HRP2 was appropriately coupled 
to the microspheres
HRP2-coupled microspheres were incubated with serial 
dilutions of 3 mAb to HRP2 and control mAb (Fig.  1). 
Based on a cut-off of the mean plus 3 standard devia-
tions (SD) of the irrelevant mAb control, mAb 2G12 (IgG) 
had a titre of >1:100,000 and mAb 87 and 1E1 had titres 
of  >1:1000 on both recombinant HRP2 proteins. The 
relationship between MFI and log Ab dilution was linear 
between 500 and 18,000 MFI, demonstrating a direct rela-
tionship between antibody concentration and MFI. These 
results confirmed that epitopes important in HRP2-based 
RDT are correctly displayed on the microspheres.
Titration of pooled human plasma
For this study, plasma from 11 Cameroonian 
adults >18 years of age residing in Simbok were randomly 
selected and combined in equal volumes to create a posi-
tive control (PC) and samples from 11 American adults 
were randomly selected and pooled to produce a nega-
tive control (NC). The pooled PC and NC controls were 
serially diluted and tested against the malarial antigens 
(Fig.  2). As expected, the PC had high titres of IgG for 
MSP1, MSP2, MSP3, and FV2, whereas, the NC did not. 
Surprisingly, no difference was seen between the PC and 
NC for HRP2. Therefore, the PC pool from Cameroon 
gave a robust response to the four P. falciparum antigens, 
but not to HRP2.
Comparison of IgG levels in individual Cameroonian 
and Americans
Since the PC contained samples from only 11 Cameroo-
nian adults, it was possible that only a small fraction of 
individuals had Ab to HRP2. Therefore, plasma sam-
ples from 110 Cameroonians (≥18 years of age) and 112 
Americans were screened individually for IgG Ab against 
the antigens. The frequency distribution of MFI in the 
samples when tested at a 1:100 dilution is shown in Fig. 3. 
As expected, MFI were low (<1000) in Americans for 
MSP, MSP2 and MSP3 and fewer than 5000 MFI to FV2. 
Using ROC analysis, it was easy to establish a cut-off pro-
viding  >85% sensitivity and 99% specificity (Fig.  3a–d). 
However, for HRP2, there was no difference in the fre-
quency distribution of MFI between the Cameroon and 
US samples. In fact, the highest MFI were actually found 
in the US samples (Fig. 3e, f ).
Measuring HRP2 antibody levels with increasing age
One hallmark of an acquired IgG response is an increase 
in Ab levels with repeated exposure to the antigen. 
Accordingly, antibody levels to HRP2 and the other four 
antigens were measured in plasma samples collected 
from individuals between the ages of 5 and 80+  years 
residing in the peri-urban village (Fig.  4). As expected, 
Ab levels to MSP1, MSP2 and MSP3 increased with age, 
reaching maximal levels by age 16–20  years, and Ab to 
FV2 were only detected in women of child-bearing age 
(square in Fig. 4). However, antibody levels remained low 
















































Fig. 2 Titration of pooled positive and negative plasma on malarial antigens. Tenfold serial dilutions of pooled plasma from 11 Cameroon adults 
(PC) and a pool of plasma from 11 non-malarial exposed Americans (NC) were assayed for IgG Ab to MSP1, MSP2, MSP3, FV2 and 2 recombinant 
preparations of HRP2 (A and B). Results are the mean ± SD for triplicate wells. Cut-off for positivity (mean + 3 SD) ranged from 500 to 1350 MFI at 
1:50 dilution. PC positive control (solid lines) and NC negative control (dotted lines)
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Fig. 3 Distribution of MFI for Cameroonian and American adults. MFI values for each antigen for 110 Cameroon and 112 American adults were 
divided into 9 bins of unequal sizes, in order to expand the lower part of the distribution. The ROC was used to determine optimal cut-offs (vertical 
dotted lines) for the best overall sensitivity and specificity. Cut-offs: a MSP1-42 = 793 MFI; b MSP2 = 2889 MFI; c MSP3 = 244 MFI; d FV2 = 1345 MFI, 
e and f no ROC cut‐off
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to the HRP2 proteins, without a significant age-related 
increase.
Comparison of IgM levels in malaria slide‑positive 
individuals and US controls
Although IgG Ab were not detected, HRP2 might 
induce a T-independent IgM response since the protein 
has multiple tandem repeat sequences. Because IgM 
has a short half-life, 81 plasma samples from children 
(n  =  49) and adults (n  =  32) who were slide-positive 
of P. falciparum were screened for IgM Ab, as well as 
ten randomly selected US controls (Fig.  5). US con-
trols had low reactivity for IgM Ab to HRP2-(A) (mean 
442 MFI) and HRP2-(B) (369 MFI). Unfortunately, the 
ROC method provided poor discriminatory ability for 
establishing a cut-off (e.g., sensitivity <20% with a spec-
ificity >97%). Using mean plus 3 SD of US controls sam-
ples, 11, 57 and 17% of malaria-infected Cameroonians 
had IgM Ab to MSP1, MSP2 and MSP3, respectively; 
15 and 30% had IgM Ab to HRP2-A and HRP2-B, with 
the highest MFI values for these antigens reaching only 
4930 and 3823 MFI. It is unclear if samples with values 
above cut-off actually: (1) contain Ab to HRP2; (2) were 
due to increased non-specific binding of polyclonal 
IgM (high background); or, (3) detected cross-reactive 
Ab.
Testing IgG antibody avidity
Since Ab secreted by antigen-specific B cells usually 
have higher avidity than cross-reactive Ab, the avidity 
to HRP2 was tested using the ten Cameroonian and ten 
American samples with the highest MFI to HRP2-(A) 
(Fig. 6). Ab levels in MFI to HRP2 are shown in Fig. 6a 
and avidity % remaining bound in Fig. 6b. Interestingly, 
median Ab levels and avidity values were slightly higher 
in Americans who had never been exposed to malaria 
compared to Cameroonian adults. There was no evi-
dence that plasma samples with the highest MFI con-
tained Ab that were more specific (i.e., high avidity) for 
HRP2 in malaria-exposed compared to malaria-naive 
individuals.
Testing of US plasma samples for binding to Plasmodium 
falciparum parasites
Since some American adults had IgG Ab that reacted 
with HRP2 (Fig.  3), it was possible they had Ab that 
cross-reacted with P. falciparum HRP2. Accordingly, 
samples from the six Americans with the highest MFI 
were tested by indirect immunofluorescent assay (IFA) 
for reactivity with P. falciparum-infected erythrocytes 
(Fig. 7). MAb 2G12 and 1E1 were used as positive con-
trols as they produce a characteristic HRP2 staining pat-
tern, including bright fluorescence in transport vesicles. 
None of the US samples had IgG or IgM Ab that bound 
to malaria infected-erythrocytes.
Screening HRP2 for potential Class II T cell epitopes
Among the top 100 potential T cell epitopes predicted by 
consensus (including comb.lib/smm/nn methods), sur-
prisingly only one high affinity association was found for 
any sequence within HRP2 and any HLA allele. The sin-
gle high affinity interaction predicted by the Consensus 
method was between HLA-DRB1*11.01 and HRP2 amino 
acids 14–28 (core LNLNKRLLH), a sequence located 
N-terminal to the repeat sequence. Several other potential 
T epitopes with intermediate and weak interactions were 
predicted with the N-terminal region for binding with 
11 other MHC Class II alleles. Within the repeat region 
(RII), no high affinity interactions were found; only one 
intermediate binding was predicted, which was between 
amino acids 45–113 with HLA-DQA1*05:01/DQB1*03:01 
(mean IC50 value 108  nM) and one weak interaction 
between with HLA-DRB3*01:01 (mean IC50 of 3862 nM). 
No T cell epitopes were predicted at the C-terminus. A 
large number of HRP-2 sequences with high affinity bind-
ing for multiple Class II alleles was not found, suggesting 
HRP2 might not be able to provide adequate T cell help 
for generation of an acquired memory B cell response.
Discussion
HRP2 is a unique protein, both in amino acid sequence 
and protein structure. It is 65–85  kDa protein made up 
of 35% histidine, 40% alanine and 12% aspartate [19, 23] 
that consists primarily of the repeat sequences AHH and 
AHHAAD [19, 23]. Once synthesized, HRP2 is trans-
ported via vesicle to the infected erythrocyte mem-
brane, where [3H]-labelling studies show that galactose is 
attached either during, or just before, HRP2 is released 
into plasma [23]. Although the structure of HRP2 has 
been difficult to determine, data predict the repeat 
sequences form a 3/10 helix or a tightly coiled α-helix 
(See figure on next page.) 
Fig. 4 Change in antibody levels with age. Ab levels were measured for 132 individuals aged 5 to 80+ years. Horizontal lines indicate the median 
for each group. Since only pregnant women produce Ab to FV2, only women over 16 years of age had Ab to this antigen (Ab positive women 
are located within the square). (Sample size: n = 9 individuals, <10 years; n = 12, 10–15 years; n = 8, 16–20 years; n = 19, 26–30 years; n = 29, 
31–40 years; n = 13, 41–50 years; n = 27, >50 years)


















































































































































































































































































































































































































































































































































Fig. 5 IgM levels to malarial antigens. Plasma from 81 individuals who were blood-smear positive for P. falciparum were screened for IgM Ab to the 
antigens shown. The dotted vertical line identifies the centre of the bin where the value for the mean + 3 SD for US control samples is located
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[23]. Thus, HRP2 is very different from known protein 
antigens.
HRP2 was initially selected for diagnosis of falcipa-
rum malaria because it is highly conserved, synthesized 
by ring-stage parasites, and secreted into plasma. Lee 
et  al. sequenced 448 global isolates and reported that 
the sequences DAHHAAHAHH (recognized by mAb 
2G12) and AHHAHHV (recognized by mAb 1E1) were 
present in 448/448 (100%) and 45/448 (99.3%) of the 
isolates, respectively, and that multiple copies of these 
repeat sequences were present (average 18.4 copies/iso-
late) [16, 17]. The binding of monoclonal Ab to HRP2-
coupled microspheres demonstrates that epitopes in the 
repeat sequence were correctly displayed. Since individu-
als infected with P. falciparum are exposed to the repeat 
sequences of HRP2, they should have Ab to HRP2 if the 
protein is immunogenic.
The initial goal was to determine the prevalence, 
class, subclass, and avidity of Ab to HRP2 in different 
age groups living in a malaria-endemic region of Cam-
eroon. The samples, collected between 1994 and 1999, 
were from a cross-sectional malaria prevalence study 
in Simbok village, at which time the estimated ento-
mological inoculation rate was  ~556 infectious bites 
annually [12]. Study subjects had been infected with P. 
falciparum multiple times. Based on the characteristic of 
acquired B cell responses, one would expect to find Ab 
to HRP2 in Cameroonian, but not American adults and 
that Ab prevalence, amount and avidity would increase 
with age. Interestingly, the results found no evidence of 
an acquired immune response to HRP2, since values for 
IgG to HRP2 were similar in exposed and unexposed 
individuals and IgG levels did not increase with age 
(Figs. 2, 3). The lack of IgG was not due to poor quality 
of the plasma samples, because the samples contained 
high levels of Ab to the other malarial antigens (MSP1, 
MSP2, MSP3) when tested simultaneously in the multi-
plex assay (Fig. 2). Because HRP2 has tandem repeats, it 
might function as a T-independent antigen. This possibil-
ity seemed unlikely since a related plasmodial parasite, 
Plasmodium yoelii, lacks both type 1 or 2 T-independ-
ent antigens, i.e., infected athymic mice fail to produce 
Ab to any malarial antigen [24]. The mice, however, had 
activated B-cells that did not secrete Ab in the absence 
of T cell help. Nonetheless, plasma from 81 Camerooni-
ans who were blood-smear positive of P. falciparum were 
tested for IgM Ab to HRP2 (Fig.  4). A few individuals 
had borderline-positive IgM values for HRP2 compared 
to the US negative controls but MFI were very low. Since 
total IgM levels are elevated during P. falciparum infec-
tion due to antigen-specific and polyclonal B cell activa-
tion, it was difficult to know if values above the arbitrary 
cut-off were due to IgM Ab, non-specific binding, or 
































Fig. 6 Testing the strength (avidity) of IgG binding in plasma the 10 Cameroonian and 10 USA adults with the highest MFI for HRP2-A. The 10 
American and 10 Cameroonian plasma samples with the highest MFI for HRP2 were incubated with 1% BSA-PBS and 3 M NH4SCN in 1% BSA-PBS 
and the percentage of Ab that remained bound was determined. Results showed that at 1:100 dilution all plasma samples had consistently low 
level binding to HRP2 and there was no difference in the strength of interaction between plasma from Americans and Cameroonian adults. Horizon-
tal bar median for the group
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plasma samples, the six samples with the highest MFI for 
HRP2 were tested for IgG and IgM binding to P. falcipa-
rum-infected erythrocytes by IFA (Fig.  6). None of the 
US samples tested positive, suggesting that the Ameri-
cans did not have Ab that cross-reacted with P. falcipa-
rum; rather, the samples simply had high backgrounds. 
The finding that antibody avidity was similar between 
Americans and Cameroonians for HRP2 (Fig.  6b) sup-
ports the conclusion that Cameroonians adults did not 
have an acquired immune response to HRP2, that is, a 
response that had undergone somatic hypermutation, 













Fig. 7 IFA staining of mAb to HRP2 and the four US samples with highest MFI for HRP2 a, b MAb 1E1 and 2G12 showed strong reactivity with the 
cytoplasm, transport vesicles within the erythrocyte cytosol, and at the surface of the infected erythrocyte. c–f In contrast, none of the four USA 
plasma samples (with the highest MFI in the multiplex analyte assay was positive (tested at 1:50 dilution). Apple–green Ab staining. Slides were 
counter-stained with DAPI to identify parasite nuclei (MFI values for the sample are shown in parentheses)
Page 12 of 14Taylor et al. Malar J  (2017) 16:58 
Results from the current studies are similar to those 
reported previously. Using an IgG ELISA assay, Das 
et al. reported that OD of plasma samples were the same 
between malaria-naive individuals and those who had 
acute symptomatic infections, asymptomatic infections 
and uninfected adults residing in a malaria-endemic area 
in India [11]. Biswas et  al. used a similar ELISA with a 
cut-off based on replicates of a pool of five negative 
plasma samples and reported detecting IgM Ab to HRP2 
in patients at enrolment. However, following drug treat-
ment, IgM Ab quickly declined and IgG Ab to HRP2 were 
detected 15–28 days post treatment. Patients in the above 
study had asymptomatic infections, showing they had 
sufficient immunity to control their infections. Yet they 
tested positive for IgM at enrolment and only produced 
IgG several weeks after drug treatment, thus display-
ing characteristics of a primary Ab response, suggest-
ing they lacked a memory B cell response to HRP2 prior 
to the ongoing infection. Ho et al. used a similar ELISA 
and their ‘raw data’ looks similar to that found in Fig. 2 
of the current study. The biggest difference between the 
two studies is the method used to establish the cut-off for 
positivity. Ho et al. used a pool of six samples from non-
malaria exposed individuals as a negative control and 
converted OD into arbitrary units based on a pool of five 
samples with the highest OD to HRP2 [9]. They reported 
that 19/75 individuals with acute malaria in Cambodia, 
Nigeria and Philippines were Ab-positive and three/28 
asymptomatic Solomon Island residents were positive. 
However, most positive samples had antibody levels only 
one to three times higher than the cut-off, with only two 
plasma samples having Ab levels fivefold and 16.7-fold 
above cut-off. In the current study, 112 malaria-naive 
control individuals were used, providing data for a wide 
range of malaria-naive individuals, including individuals 
with other infections (Fig. 2). Compared to MSP1, MSP2 
and MSP3, a highly variable background level of reac-
tivity was found for HRP2 in malaria-naive adults, with 
some individuals having 20-fold higher levels than others. 
Using plasma from a limited number of healthy controls 
to establish a cut-off for malaria-infected individuals with 
hyper-gammaglobinaemia may not be optimal. Overall, 
none of the above studies found high IgG antibody levels 
to HRP2 in people living in malaria-endemic regions. It is 
unlikely that IgG Ab to HRP2 significantly alter the sensi-
tivity of HRP-2-based diagnostic assays.
The lack of Ab may help explain why HRP2-based 
assays work as well as they do. First, if Ab were present, 
soluble HRP2 would rapidly form immune complexes 
and quickly be cleared by the spleen. HRP2 is detectable 
in plasma for  >28  days after parasite elimination, sug-
gesting that the protein circulates freely in plasma and is 
slowly removed by glomerular filtration and proteolysis. 
Second, the detection thresholds in RDTs is very low, for 
example Marquat et  al. reported that the lower limit of 
detection for four RDTs was between 6.9 and 27.8  ng/
ml [25], an amount of antigen that would be neutral-
ized by microgram levels of Ab. Finally, absence of Ab 
could explain why an association exists between parasite 
burden and disease severity, i.e., the more parasites, the 
more HRP2 in circulation. The uniqueness of HRP2 and 
its apparent poor immunogenicity would help explain 
why HRP2-based tests work the way they do.
Finally, the question is, why do people not produce Ab 
to HRP2? A number of possibilities exist. First, soluble 
proteins are usually poorly immunogenic in the absence 
of adjuvants. This explanation seems unlikely since HRP2 
is also associated with the erythrocyte membrane. Sec-
ondly, endogenous histidine rich glycoprotein (HRG) 
exists in human plasma that also binds to divalent metal 
ions. However, Ab to HRG do not bind to HRP2 and mAb 
to HRP2 do not bind to HRG [23], making it unlikely 
humans are immunologically tolerant to HRP2. Third, 
Das et al. found that peripheral blood mononuclear cells 
from malaria-exposed adults proliferated and secreted 
IL-4 when stimulated in  vitro with MSP1-42, but not 
with HRP2 [11]. They suggested that HRP2 might sup-
press some immune responses, including T cell prolifera-
tion, IFNɤ secretion and CD69 expression [26]. Fourth, 
HRP2 may lack an adequate number of T cell epitopes 
to induce an acquired B cell response in most individu-
als. Using predictive models, only one predictive Class II 
T cell epitope was identified, namely, the core sequence 
LNLNKRLLH located before the repeat sequences that 
only has high affinity for DRB1*011.01. Within the repeat 
region, which contains the majority of amino acids, only 
one T epitope with intermediate-binding was predicted, 
i.e., amino acids 45 to 113 with HLA-DQA1*05:01/
DQB1*03:01 and one weak interaction with DRB3*01:01. 
A search of the Allele Frequency Net Database showed 
these alleles are not common in Africa, e.g., DRB1*11.01-
DQA1*05:01 -DQB1*03:01 is present in 1.8–2.6% in 
Ethiopia and HLA-DRB3*01:01 was not reported. Since 
HRP2 has a unique amino acid composition and struc-
ture, it is plausible it may not be highly immunogenic in 
humans.
Conclusions
These data support the conclusion that most individuals 
in malaria-endemic areas do not develop an acquired B 
cell immune response to HRP2. Lack of Ab to HRP2 help 
explain why HRP2-based assays are able to detect nano-
gram amounts of HRP2 and why soluble HRP2 continues 
to circulate for a long time after parasite clearance.
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